JP2019530427A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019530427A5 JP2019530427A5 JP2018568216A JP2018568216A JP2019530427A5 JP 2019530427 A5 JP2019530427 A5 JP 2019530427A5 JP 2018568216 A JP2018568216 A JP 2018568216A JP 2018568216 A JP2018568216 A JP 2018568216A JP 2019530427 A5 JP2019530427 A5 JP 2019530427A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- seq
- heavy chain
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 108010071690 Prealbumin Proteins 0.000 claims 10
- 102000009190 Transthyretin Human genes 0.000 claims 10
- 238000000034 method Methods 0.000 claims 9
- 206010002022 amyloidosis Diseases 0.000 claims 7
- 230000001404 mediated effect Effects 0.000 claims 7
- 239000012472 biological sample Substances 0.000 claims 5
- 239000013068 control sample Substances 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 3
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 2
- 208000006029 Cardiomegaly Diseases 0.000 claims 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 208000019428 Ligament disease Diseases 0.000 claims 2
- 208000023835 Tendon disease Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 210000003403 autonomic nervous system Anatomy 0.000 claims 2
- 210000001508 eye Anatomy 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 210000002216 heart Anatomy 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000003041 ligament Anatomy 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 230000007082 Aβ accumulation Effects 0.000 claims 1
- 102000009490 IgG Receptors Human genes 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 208000005198 spinal stenosis Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 239000004475 Arginine Substances 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/201,416 | 2016-07-02 | ||
| US15/201,416 US9879080B2 (en) | 2015-01-28 | 2016-07-02 | Anti-transthyretin antibodies |
| PCT/IB2017/053987 WO2018007923A2 (en) | 2016-07-02 | 2017-06-30 | Anti-transthyretin antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019530427A JP2019530427A (ja) | 2019-10-24 |
| JP2019530427A5 true JP2019530427A5 (cg-RX-API-DMAC7.html) | 2020-08-13 |
| JP7016470B2 JP7016470B2 (ja) | 2022-02-07 |
Family
ID=59506312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568216A Active JP7016470B2 (ja) | 2016-07-02 | 2017-06-30 | 抗トランスサイレチン抗体 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3478715A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7016470B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018007923A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| CN111757730A (zh) | 2017-10-06 | 2020-10-09 | 普罗塞纳生物科学有限公司 | 检测甲状腺素运载蛋白的方法 |
| MX2020003041A (es) | 2017-10-06 | 2020-10-05 | Prothena Biosciences Ltd | Anticuerpos anti-transtiretina. |
| AU2018375356A1 (en) | 2017-11-29 | 2020-05-14 | Neotope Neuroscience Limited | Lyophilized formulation of a monoclonal antibody against transthyretin |
| AU2019374418B2 (en) | 2018-11-09 | 2025-10-02 | Neurimmune Ag | Patient-derived amyloid xenograft non-human animal model |
| AU2021272369A1 (en) | 2020-05-12 | 2023-01-19 | Neurimmune Ag | Combination therapy for TTR amyloidosis |
| WO2023099788A1 (en) | 2021-12-03 | 2023-06-08 | Neurimmune Ag | Novel potency assay for antibody-based drugs and useful means therefor |
| TW202434624A (zh) | 2022-11-15 | 2024-09-01 | 瑞士商紐立慕公司 | 治療或預防甲狀腺素運載蛋白調節之澱粉樣變性的方法 |
| WO2024240562A1 (en) | 2023-05-19 | 2024-11-28 | Neurimmune Ag | Novel immunotherapy for musculoskeletal disorders and conditions |
| WO2025104243A1 (en) | 2023-11-15 | 2025-05-22 | Neurimmune Ag | Anti-transthyretin antibody, compositions comprising said antibody and methods for treating or preventing transthyretin-mediated amyloidosis |
| TW202525341A (zh) | 2023-12-15 | 2025-07-01 | 丹麥商諾佛 儂迪克股份有限公司 | 穩定的液體調配物 |
| WO2025238147A1 (en) | 2024-05-15 | 2025-11-20 | Neurimmune Ag | Maintenance treatment of cardiac ttr amyloidosis using anti-transthyretin antibodies |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69230142T2 (de) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Technology Ltd. | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5877218A (en) | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| CA2625839A1 (en) | 1999-02-05 | 2000-08-10 | Samsung Electronics Co., Ltd. | Image texture retrieving method and apparatus thereof |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| IL166244A0 (en) | 2001-07-12 | 2006-01-15 | Jefferson Foote | Super humanized antibodies |
| AU2002361886A1 (en) | 2001-12-28 | 2003-07-24 | Abgenix, Inc. | Antibodies against the muc18 antigen |
| EP1567652B1 (de) | 2002-11-29 | 2007-08-22 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Neue neomycin-phosphotransferase-gene und verfahren zur selektion von hochproduzierenden rekombinanten zellen |
| DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
| ATE433110T1 (de) | 2004-11-10 | 2009-06-15 | Boehringer Ingelheim Pharma | Verwendung von durchflusszytometrischer analyse zur optimierung von zellbankingstrategien für cho-zellen |
| US8703096B2 (en) | 2006-04-21 | 2014-04-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Beta-amyloid PET imaging agents |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| EP2609932B1 (en) | 2006-12-01 | 2022-02-02 | Seagen Inc. | Variant target binding agents and uses thereof |
| DK2126093T3 (da) | 2007-03-02 | 2013-01-07 | Boehringer Ingelheim Pharma | Forbedring af proteinfremstilling |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| US9534048B2 (en) * | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
| US9790269B2 (en) * | 2013-02-08 | 2017-10-17 | Misfolding Diagnostics, Inc. | Transthyretin antibodies and uses thereof |
| TWI718121B (zh) | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
-
2017
- 2017-06-30 WO PCT/IB2017/053987 patent/WO2018007923A2/en not_active Ceased
- 2017-06-30 EP EP17746543.2A patent/EP3478715A2/en active Pending
- 2017-06-30 JP JP2018568216A patent/JP7016470B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019530427A5 (cg-RX-API-DMAC7.html) | ||
| JP2019532617A5 (cg-RX-API-DMAC7.html) | ||
| JP2019530428A5 (cg-RX-API-DMAC7.html) | ||
| US10882904B2 (en) | Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies | |
| JP6592059B2 (ja) | アルファシヌクレインを認識するヒト化抗体 | |
| JP2020536532A5 (cg-RX-API-DMAC7.html) | ||
| JP7623699B2 (ja) | タウ認識抗体 | |
| JP2018506277A5 (cg-RX-API-DMAC7.html) | ||
| JP2018510617A5 (cg-RX-API-DMAC7.html) | ||
| JP2018509889A5 (cg-RX-API-DMAC7.html) | ||
| TW201029662A (en) | Novel antigen binding proteins | |
| EP3350220A1 (en) | Anti-pro/latent-myostatin antibodies and uses thereof | |
| CN103145840A (zh) | Il-12/p40结合蛋白 | |
| TW201031421A (en) | IL-1 binding proteins | |
| CN108367075A (zh) | 4-1bb结合蛋白及其用途 | |
| TW201210612A (en) | Humanised antigen binding proteins | |
| EP3823986A1 (en) | Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of neuropathic pain | |
| RU2015136078A (ru) | Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний | |
| CN104744591A (zh) | β淀粉样蛋白结合蛋白 | |
| RU2014150433A (ru) | Улучшенные антитела антагонисты против gdf-8 и их применения | |
| TW201333039A (zh) | 雙可變域免疫球蛋白及其用途 | |
| JP2016500656A (ja) | 代謝性疾患及び心臓血管疾患を治療するためのｔｏｌｌ様受容体３アンタゴニスト | |
| JP2013508292A5 (cg-RX-API-DMAC7.html) | ||
| US12331113B2 (en) | Anti-human NR1 antibody derivative | |
| WO2014028748A1 (en) | Interleukin 2 antibodies and antibody complexes |